A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
NCT00198159
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Refractory Germ Cell Tumors Expressing EGRF
Interventions
DRUG:
ZD1839 Iressa
Sponsor
Indiana University
Collaborators
[object Object]